《大行報告》交銀國際升金斯瑞(01548.HK)目標價至27.6元 業績具韌性
交銀國際發表報告指,金斯瑞(01548.HK)去年收入韌性強,利潤率超預期。去年公司收入8.4億美元,按年增長34.2%;經調整淨虧損收窄至2.98億。整體毛利率48.8%,主要得益於細胞治療板塊毛利率的快速提升。隨著海外融資在首季逐步回暖、蓬勃生物完成團隊優化、海外市場開拓提速,該行預計全年CDMO業務將有所好轉,超公司指引的可能性較大。
該行將集團2024至2025年收入預測略微下調0.6%和0.5%,但基於更高的經營利潤率假設,2024年淨虧損預測減少4%、2025年淨利潤從9.4億增加至14.8億;同時首次引入2026年盈利預測,料收入21.6億美元、淨利潤1.74億,四大業務板塊全部實現盈利,該行將其目標價升至27.6元,評級「買入」。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.